Veracyte
Yahoo Finance • 2 months ago
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
Findings are from ancillary study of phase 3 STAMPEDE trial Data support company’s plan to expand Decipher Prostate test to patients with metastatic disease SOUTH SAN FRANCISCO, Calif., September 15, 2024--(BUSINESS WIRE)--Veracyte, Inc.... Full story
Yahoo Finance • 6 months ago
Is Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount?
Key Insights The projected fair value for Veracyte is US$35.05 based on 2 Stage Free Cash Flow to Equity Current share price of US$20.12 suggests Veracyte is potentially 43% undervalued Analyst price target for VCYT is US$30.60 which is 1... Full story
Yahoo Finance • 6 months ago
Q1 2024 Veracyte Inc Earnings Call
Participants Shayla Gorman; Senior Director, Investor Relations; Veracyte Inc Marc Stapley; Chief Executive Officer, Director; Veracyte Inc Rebecca Chambers; Chief Financial Officer; Veracyte Inc Andrew Brackmann; Analyst; William Blai... Full story
Yahoo Finance • 6 months ago
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
SOUTH SAN FRANCISCO, Calif., April 22, 2024--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company man... Full story
Yahoo Finance • 8 months ago
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
SOUTH SAN FRANCISCO, Calif., February 27, 2024--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive... Full story
Yahoo Finance • 11 months ago
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
Non-invasive genomic test is designed to help physicians guide next steps for current and former smokers with lung nodules SOUTH SAN FRANCISCO, Calif., November 29, 2023--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that clini... Full story
Yahoo Finance • last year
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
Findings from prospective, population-based study presented at ESMO Breast Cancer Congress 2023 SOUTH SAN FRANCISCO, Calif., May 12, 2023--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna... Full story
Yahoo Finance • 2 years ago
Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript May 4, 2023 Operator: Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2023 Financial Results Webcast. At this time, all participants are in listen... Full story
Yahoo Finance • 2 years ago
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Exagen Inc. SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Di... Full story
Yahoo Finance • 2 years ago
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
Meta-analysis of 13 independent studies suggests genomic test performs even better in real-world clinical practice as compared to original clinical validation study SOUTH SAN FRANCISCO, Calif., December 15, 2022--(BUSINESS WIRE)--Veracyte... Full story
Yahoo Finance • 2 years ago
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
Findings presented at the European Respiratory Society International Congress 2022 SOUTH SAN FRANCISCO, Calif., September 07, 2022--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomi... Full story
Yahoo Finance • 2 years ago
Veracyte Announces Second Quarter 2022 Financial Results
Grew Total Revenue to $72.9 million, an Increase of 32% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., August 02, 2022--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for... Full story
Yahoo Finance • 2 years ago
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
Findings from a large, multi-cohort study suggest the genomic test can improve care for lung nodule patients with inconclusive bronchoscopy results SOUTH SAN FRANCISCO, Calif., July 13, 2022--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT)... Full story
Yahoo Finance • 2 years ago
10 Small-Cap Stocks to Buy According to Ken Fisher
In this article, we discuss 10 small-cap stocks to buy according to Ken Fisher. If you want to skip our detailed analysis of Fisher Asset Management's philosophy, hedge fund returns, and history, go directly to 5 Small-Cap Stocks to Buy Ac... Full story
Yahoo Finance • 3 years ago
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
SOUTH SAN FRANCISCO, Calif., May 04, 2022--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that new consensus data from a survey of leading breast cancer oncologists in Europe suggest the importance of gene expression profil... Full story
Yahoo Finance • 3 years ago
Veracyte Announces First Quarter 2022 Financial Results
Grew Total Revenue to $67.8 million, an Increase of 85% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 03, 2022--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the... Full story
Yahoo Finance • 3 years ago
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
Intellia Therapeutics, Inc. CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based tec... Full story
